NCT06675539 Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS)
| NCT ID | NCT06675539 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Etablissement Public de Santé Barthélemy Durand |
| Condition | Addiction, Substance |
| Study Type | OBSERVATIONAL |
| Enrollment | 545 participants |
| Start Date | 2024-11-11 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 545 participants in total. It began in 2024-11-11 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to validate the French version of the PAWSS scale in a population of patients with Alcohol Use Disorders. Prediction of Alcohol Withdrawal Severity Scale (PAWSS) has an excellent psychometric characteristics and predictive value of complicated alcohol withdrawal. The main question it aims to answer is: Are the psychometric properties of the French version of the PAWSS scale comparable to those of the English version in a population of alcohol use disorders subjects? AUDs participants are included and followed for three days during their hospitalization, They will performed several scales and surveys (DSM-5 AUD criteria, AUDIT, French version of PAWSS and CIWA-AR).
Eligibility Criteria
Inclusion Criteria: * Male or female, aged 18 to 60 years * Subjects with DSM-5 criteria for alcohol use disorders (AUD) * Subjects hospitalized for scheduled withdrawal or patients developing alcohol withdrawal hospitalized for another reason. * Subjects who understand French * Subject affiliated to the French social security system * Subject having given their written consent to the study Exclusion Criteria: * Subjects transferred from other hospitalization services for whom a withdrawal syndrome could have already been treated. * Subjects scheduled for discharge within 48 hours. * Subjects with known uncontrolled epilepsy. * Subjects unable to understand the questionnaire. * Subjects unable to give consent or not volunteering for the study. * Subjects under guardianship or curatorship.
Contact & Investigator
Alain Dervaux
PRINCIPAL INVESTIGATOR
Etablissement Public de Santé Barthélemy Durand
Frequently Asked Questions
Who can join the NCT06675539 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Addiction, Substance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06675539 currently recruiting?
Yes, NCT06675539 is actively recruiting participants. Contact the research team at adelaide.aduayi@eps-etampes.fr for enrollment information.
Where is the NCT06675539 trial being conducted?
This trial is being conducted at Étampes, France.
Who is sponsoring the NCT06675539 clinical trial?
NCT06675539 is sponsored by Etablissement Public de Santé Barthélemy Durand. The principal investigator is Alain Dervaux at Etablissement Public de Santé Barthélemy Durand. The trial plans to enroll 545 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.